Court order gives Braeburn new hope for its opioid-abuse disorder drug
July 30, 2019 at 12:37 PM EDT
The court sided with the Plymouth Meeting company's appeal of an FDA decision that blocked final approval of Braeburn's Brixadi medicine because of a competing product's market exclusivity.
